HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study [0.03%]
靶向HBsAg和TLR7/8的抗体偶联药物诱导AAV/HBV小鼠持续抗HBV作用：初步研究
Xinya Ye,Xiaoqing Chen,Han Liu et al.
Xinya Ye et al.
Hepatitis B virus (HBV) infection is a significant global health concern due to elevated immunosuppressive viral antigen levels, the host immune system's inability to manage HBV, and the liver's immunosuppressive conditions. While immunothe...
First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region [0.03%]
通过Fc区糖基重构对天然山羊IgG抗体进行首个位点特异性修饰的方法
Michael E Dolan,Amissi Sadiki,Leo Lei Wang et al.
Michael E Dolan et al.
Despite their triumph in treating human diseases, antibody therapies for animals have gained momentum more slowly. However, the first approvals of animal antibodies for osteoarthritic pain in cats and dogs may herald the dawn of a new era. ...
rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering [0.03%]
一种用于计算工程化重组抗体设计的新型工作流程 RabDesFlow
Sowmya Ramaswamy Krishnan,Divya Sharma,Yasin Nazeer et al.
Sowmya Ramaswamy Krishnan et al.
Recombinant antibodies (rAbs) have emerged as a promising solution to tackle antigen specificity, enhancement of immunogenic potential and versatile functionalization to treat human diseases. The development of single chain variable fragmen...
Correction to: A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications [0.03%]
correction to：“发现阶段双特异性抗体可制造性研究及优化的个例分析及其意义》
[This corrects the article DOI: 10.1093/abt/tbae013.]. © The Author(s) 2024. Published by Oxford University Press on behalf of Antibody Therapeutics.
Published Erratum
Antibody therapeutics. 2024 Aug 27;7(3):281. DOI:10.1093/abt/tbae021 2024
A pan-allelic human SIRPα-blocking antibody, ES004-B5, promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response [0.03%]
全等位基因的人源化SIRPα阻断抗体ES004-B5通过增强巨噬细胞吞噬作用和随后诱导有效的T细胞反应促进肿瘤杀伤作用
Xiaofeng Niu,Chunnian Wang,Haixia Jiang et al.
Xiaofeng Niu et al.
As a major immune cell type in the tumor microenvironment, tumor-associated macrophages secrete suppressive factors that can inhibit antitumor immunity and promote tumor progression. One approach trying to utilize macrophages for immunother...
Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs [0.03%]
基于单克隆哺乳动物细胞展示的Fc工程改善与FcγRs结合的亲和力和特异性
Zening Wang,Minhyo Kang,Afshin Ebrahimpour et al.
Zening Wang et al.
Fc optimization can significantly enhance therapeutic efficacy of monoclonal antibodies. However, existing Fc engineering approaches are sub-optimal with noted limitations, such as inappropriate glycosylation, polyclonal libraries, and util...
Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies [0.03%]
蛋白质语言模型能够预测单特异性、双特异性及仅重链抗体的多反应性
Xin Yu,Kostika Vangjeli,Anusha Prakash et al.
Xin Yu et al.
Background: Early assessment of antibody off-target binding is essential for mitigating developability risks such as fast clearance, reduced efficacy, toxicity, and immunogenicity. The baculovirus particle (BVP) binding a...
A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications [0.03%]
一种双特异性抗体在发现阶段的可制造性分析和优化的案例研究及其影响
Shuang Wang,Weijie Zhang,Baotian Yang et al.
Shuang Wang et al.
The manufacturability assessment and optimization of bispecific antibodies (bsAbs) during the discovery stage are crucial for the success of the drug development process, impacting the speed and cost of advancing such therapeutics to the In...
Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity [0.03%]
一种针对HER2的携带伊利替康（Eribulan）并具有强旁观者效应和ICD作用的抗体药物偶联物BB-1701的临床前研究
Yang Wang,Bing Xia,Lixia Cao et al.
Yang Wang et al.
Background: Several HER2-targeting antibody-drug conjugates (ADC) have gained market approval for the treatment of HER2-expressing metastasis. Promising responses have been reported with the new generation of ADCs in pati...
A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants [0.03%]
一种VHH单域平台，能够发现并开发针对SARS-CoV-2变异体的单一特异性抗体和模块化双特异性中和抗体
Marisa L Yang,Tom Z Yuan,Kara Y Chan et al.
Marisa L Yang et al.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, escape coronavirus disease 2019 therapeutics and vaccines, and jeopardize public health. To combat SARS-CoV-2 antigenic escape, we developed a rapid, high-thr...